The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...

SHANGHAI, March 19 (Reuters) - AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and an ...

A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...